Finally, recent data supported the view that homologous recombination deficiency (HRD) occurs in endometrial cancers and is largely restricted to non-endometrioid, TP53-mutant endometrial cancers, the spectrum of germline mutations detected including BRCA1/2 (breast cancer type 1/2 susceptibility protein) and RAD51 (DNA repair protein RAD51 homolog 1) among others (Ring et al. 2016; De Jonge et al. 2019). The gene discussed is TP53; the disease is endometrial cancer.